Published by If you or a loved one were diagnosed with cutaneous T-cell lymphoma (CTCL) or another serious T-cell lymphoma after using Dupixent (dupilumab), you may be entitled to compensation through a pharmaceutical product liability lawsuit.
Our experienced legal team is committed to supporting patients who have suffered harm due to inadequate warnings and delayed diagnosis. We will guide you through the process and fight for the justice and recovery you deserve.
Click below for a Free Confidential Case Evaluation or call us toll-free 24/7 at (866) 588-0600.
Table Of Contents
What’s the Problem?
This issue focuses on claims that users of Dupixent (dupilumab) – a medication developed by Sanofi and Regeneron for treating eczema, asthma, nasal polyps, and other inflammatory conditions – developed cutaneous T-cell lymphoma (CTCL), a rare and aggressive skin-based cancer.
Multiple studies have documented significantly increased CTCL risk, with adjusted odds ratios ranging from 3 to over 4.5, and in some cohorts over 14 times higher for combined mature T-cell and NK-cell lymphomas. This increased risk has been observed not only in atopic dermatitis patients but also in asthma patients treated with Dupixent, highlighting the broader implications for those using the drug.
Plaintiffs allege that manufacturers failed to warn patients and healthcare providers of this serious risk, which has led to delayed cancer diagnosis and worsened outcomes. Although litigation is in its early stages, we are actively investigating potential claims involving CTCL and other T-cell malignancies tied to Dupixent use.
Latest Dupixent Updates
- September 2025 – Law firms announce investigations and begin accepting potential CTCL claimants nationwide [1].
- August 2025 – Medical experts indicate Dupixent users are nearly nine times more likely to report CTCL to the FDA than users of other eczema treatments, intensifying scrutiny of safety labeling [2].
- March 2025 – FDA’s FAERS internal review reportedly identified strong safety signals linking Dupixent with CTCL, prompting increased regulatory and legal interest [3].
Dupixent Statistics
- Reported risk levels – Early studies show an adjusted CTCL risk increase from 3- to 4.5-fold, and one model estimated over 14-fold risk for certain lymphoma subtypes [4].
- Case growth – While precise lawsuit counts are unpublished, multiple firms report rising claim inquiries and formal early-stage filings.
- Market use – Dupixent, approved for conditions like atopic dermatitis (2017), asthma, eosinophilic disorders, and newly bullous pemphigoid (2025), is increasingly prescribed across diverse patient populations.
FDA Reports and Statistics
Analysis of FAERS data spanning Q2 2016–Q4 2023 identified over 5,300 suspected adverse event reports linked to dupilumab, including new signals such as dry eye, blurred vision, and rebound eczema [5].
This raises concerns beyond the relatively mild side effects seen in clinical trials. No formal FDA warning specific to lymphoma has been issued to date, but internal safety alerts and growing case reports suggest regulatory interest is escalating.
Dupixent Injuries & Side Effects
The range of reported Dupixent side effects includes both common outcomes from trials and emerging serious concerns related to lymphoma.
- Common adverse effects – Injection site reactions, conjunctivitis, nasopharyngitis, and dry skin were frequently observed in trials.
- Lymphoma risks (CTCL and other T-cell cancers) – Multiple studies show significantly elevated lymphoma risk in Dupixent users versus controls.
- Ocular and dermatologic issues – FAERS surveillance data points to dry eye, blurred vision, and rebound dermatitis as additional areas of concern.
Do You Qualify for a Dupixent Lawsuit?
- You received Dupixent (dupilumab) between 2017 and 2025.
- You were later diagnosed with CTCL or another T-cell lymphoma.
- Your lymphoma symptoms were not present before starting Dupixent, or they worsened during treatment.
- You have medical diagnosis documentation (biopsy, dermatology report, pathology results).
- You have records of Dupixent use (prescription, pharmacy or clinical dosing info).
Evidence Required for a Dupixent Lawsuit
- Medical records – Dermatology notes, pathology reports, lymphoma staging, treatment history, and Dupixent prescribing records.
- Product evidence – Prescription history, dosage logs, and duration of treatment.
- Symptom timeline – Dates of Dupixent initiation, onset of CTCL signs, biopsy or diagnostic confirmation.
- Expert opinions – Medical expert analysis linking lymphoma to Dupixent exposure, if available.
Damages You Can Recover
- Medical expenses – Costs for diagnosis, treatment (chemotherapy, radiation, skin-directed therapy), and ongoing care.
- Lost income and earning capacity – If illness affected work ability.
- Pain and suffering – Physical discomfort, emotional distress, quality of life losses.
- Punitive damages – Possible where failure to warn or deceptive practices are proven.
At this early stage, specific settlement ranges are not available, but outcomes will depend on injury severity and the strength of evidence.
Dupixent Recall Information
No recall has been issued. Dupixent remains on the market with new FDA indications (e.g., bullous pemphigoid, June 2025). However, increased regulatory scrutiny and safety alerts related to lymphoma signal potential future actions. Staying informed and preserving evidence is essential for affected patients.
Statute of Limitations for Dupixent Lawsuits
Product liability statutes of limitations vary by state but generally allow 2 to 4 years from diagnosis or injury discovery. In some jurisdictions, the clock may begin when a patient learns of a possible drug-related harm. Because lymphoma diagnosis may be delayed, consulting an attorney early is critical to avoid missed deadlines.
Related Articles:
FAQs
1. Can Dupixent cause lymphoma?
Studies indicate a significantly increased risk of CTCL and other T-cell malignancies among users.
2. Does Dupixent suppress the immune system?
Dupixent does not broadly suppress the immune system like traditional immunosuppressants. Instead, it is a monoclonal antibody that specifically targets and blocks two proteins in the immune system – interleukin-4 (IL-4) and interleukin-13 (IL-13) – which are involved in inflammatory responses.
3. What should I do if diagnosed?
Seek medical care, gather your records, and contact a legal team to evaluate your case promptly.
4. Is there a class action Dupixent lymphoma lawsuit?
No class action exists yet; current cases are individual filings or may consolidate into MDL in future.
5. Why didn’t the label warn me?
Lawsuits allege manufacturers withheld or delayed warning about lymphoma risks despite emerging evidence.
6. How long do I have to file?
Most states allow 2–4 years from date of diagnosis or awareness—consult legal counsel immediately to preserve rights.
6. What evidence is essential?
Medical diagnosis, prescription history, and timeline connecting Dupixent use to CTCL onset are key.
7. Who can be liable?
Dupixent manufacturers Sanofi and Regeneron may be defendants based on failure-to-warn claims.
References:
- https://www.presspublications.com/premium/newsusa/stories/lawyers-pursue-skin-cancer-cases-after-medication-use,67304
- https://pubmed.ncbi.nlm.nih.gov/38945437/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11903887/
- https://pubmed.ncbi.nlm.nih.gov/38588818/
- https://pubmed.ncbi.nlm.nih.gov/40074775/